Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters
Abstract Background Since the beginning of the COVID-19 pandemic, several variants of concern (VOC) have emerged for which there is evidence of an increase in transmissibility, more severe disease, and/or reduced vaccine effectiveness. Effective COVID-19 vaccine strategies are required to achieve br...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-05-01
|
| Series: | Communications Medicine |
| Online Access: | https://doi.org/10.1038/s43856-023-00302-z |
| _version_ | 1797817848515526656 |
|---|---|
| author | Catherine Berry Vincent Pavot Natalie G. Anosova Michael Kishko Lu Li Tim Tibbitts Alice Raillard Sylviane Gautheron Sheila Cummings Dinesh S. Bangari Swagata Kar Caroline Atyeo Yixiang Deng Galit Alter Cindy Gutzeit Marguerite Koutsoukos Roman M. Chicz Valerie Lecouturier |
| author_facet | Catherine Berry Vincent Pavot Natalie G. Anosova Michael Kishko Lu Li Tim Tibbitts Alice Raillard Sylviane Gautheron Sheila Cummings Dinesh S. Bangari Swagata Kar Caroline Atyeo Yixiang Deng Galit Alter Cindy Gutzeit Marguerite Koutsoukos Roman M. Chicz Valerie Lecouturier |
| author_sort | Catherine Berry |
| collection | DOAJ |
| description | Abstract Background Since the beginning of the COVID-19 pandemic, several variants of concern (VOC) have emerged for which there is evidence of an increase in transmissibility, more severe disease, and/or reduced vaccine effectiveness. Effective COVID-19 vaccine strategies are required to achieve broad protective immunity against current and future VOC. Methods We conducted immunogenicity and challenge studies in macaques and hamsters using a bivalent recombinant vaccine formulation containing the SARS-CoV-2 prefusion-stabilized Spike trimers of the ancestral D614 and the variant Beta strains with AS03 adjuvant (CoV2 preS dTM-AS03) in a primary immunization setting. Results We show that a primary immunization with the bivalent CoV2 preS dTM-AS03 elicits broader and durable (1 year) neutralizing antibody responses against VOC including Omicron BA.1 and BA.4/5, and SARS-CoV-1 as compared to the ancestral D614 or Beta variant monovalent vaccines in naïve non-human primates. In addition, the bivalent formulation confers protection against viral challenge with SARS-CoV-2 prototype D614G strain as well as Alpha and Beta variant strains in hamsters. Conclusions Our findings demonstrate the potential of a Beta-containing bivalent CoV2 preS dTM-AS03 formulation to provide broad and durable immunogenicity, as well as protection against VOC in naïve populations. |
| first_indexed | 2024-03-13T08:59:30Z |
| format | Article |
| id | doaj.art-7ddec5d298994b9fb951ab9ada5f2108 |
| institution | Directory Open Access Journal |
| issn | 2730-664X |
| language | English |
| last_indexed | 2024-03-13T08:59:30Z |
| publishDate | 2023-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Communications Medicine |
| spelling | doaj.art-7ddec5d298994b9fb951ab9ada5f21082023-05-28T11:26:13ZengNature PortfolioCommunications Medicine2730-664X2023-05-013111610.1038/s43856-023-00302-zBeta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamstersCatherine Berry0Vincent Pavot1Natalie G. Anosova2Michael Kishko3Lu Li4Tim Tibbitts5Alice Raillard6Sylviane Gautheron7Sheila Cummings8Dinesh S. Bangari9Swagata Kar10Caroline Atyeo11Yixiang Deng12Galit Alter13Cindy Gutzeit14Marguerite Koutsoukos15Roman M. Chicz16Valerie Lecouturier17Sanofi, Vaccines R&DSanofi, Vaccines R&DSanofi, Vaccines R&DSanofi, Vaccines R&DSanofi, Vaccines R&DSanofi, Vaccines R&DSanofi, Vaccines R&DSanofi, Vaccines R&DSanofiSanofiBIOQUAL IncRagon Institute of MGH, MIT, and HarvardRagon Institute of MGH, MIT, and HarvardRagon Institute of MGH, MIT, and HarvardGSKGSKSanofi, Vaccines R&DSanofi, Vaccines R&DAbstract Background Since the beginning of the COVID-19 pandemic, several variants of concern (VOC) have emerged for which there is evidence of an increase in transmissibility, more severe disease, and/or reduced vaccine effectiveness. Effective COVID-19 vaccine strategies are required to achieve broad protective immunity against current and future VOC. Methods We conducted immunogenicity and challenge studies in macaques and hamsters using a bivalent recombinant vaccine formulation containing the SARS-CoV-2 prefusion-stabilized Spike trimers of the ancestral D614 and the variant Beta strains with AS03 adjuvant (CoV2 preS dTM-AS03) in a primary immunization setting. Results We show that a primary immunization with the bivalent CoV2 preS dTM-AS03 elicits broader and durable (1 year) neutralizing antibody responses against VOC including Omicron BA.1 and BA.4/5, and SARS-CoV-1 as compared to the ancestral D614 or Beta variant monovalent vaccines in naïve non-human primates. In addition, the bivalent formulation confers protection against viral challenge with SARS-CoV-2 prototype D614G strain as well as Alpha and Beta variant strains in hamsters. Conclusions Our findings demonstrate the potential of a Beta-containing bivalent CoV2 preS dTM-AS03 formulation to provide broad and durable immunogenicity, as well as protection against VOC in naïve populations.https://doi.org/10.1038/s43856-023-00302-z |
| spellingShingle | Catherine Berry Vincent Pavot Natalie G. Anosova Michael Kishko Lu Li Tim Tibbitts Alice Raillard Sylviane Gautheron Sheila Cummings Dinesh S. Bangari Swagata Kar Caroline Atyeo Yixiang Deng Galit Alter Cindy Gutzeit Marguerite Koutsoukos Roman M. Chicz Valerie Lecouturier Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters Communications Medicine |
| title | Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters |
| title_full | Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters |
| title_fullStr | Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters |
| title_full_unstemmed | Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters |
| title_short | Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters |
| title_sort | beta containing bivalent sars cov 2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters |
| url | https://doi.org/10.1038/s43856-023-00302-z |
| work_keys_str_mv | AT catherineberry betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters AT vincentpavot betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters AT natalieganosova betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters AT michaelkishko betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters AT luli betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters AT timtibbitts betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters AT aliceraillard betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters AT sylvianegautheron betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters AT sheilacummings betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters AT dineshsbangari betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters AT swagatakar betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters AT carolineatyeo betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters AT yixiangdeng betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters AT galitalter betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters AT cindygutzeit betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters AT margueritekoutsoukos betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters AT romanmchicz betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters AT valerielecouturier betacontainingbivalentsarscov2proteinvaccineelicitsdurablebroadneutralizationinmacaquesandprotectioninhamsters |